In his role as SVP of life sciences, Ian Koenig brings broad experience to Investis Digital in communications strategy, digital marketing, investor relations and business development on behalf of biopharma globally. Mr...
As a VP of Independent Trading Group (ITG), an issuer designated market making firm, Chris Kaplan brings a more institutional approach to provide liquidity for clients with stocks that are thinly traded. ITG, which is...
Closely-held SetPoint Medical is pioneering electric stimulation of the vagus nerve in the neck as a treatment for rheumatoid arthritis (RA) and other chronic autoimmune diseases, such as Crohn’s disease, ulcerative...
After abruptly ending its hepatitis B virus program in January, Spring Bank Pharmaceuticals (NASDAQ:SBPH) is in the early stages of examining whether its family of RIG-I agonists have the potential to attack SARS-CoV-2...
Despite delays in dosing of patients at its Toronto clinic and building its network of clinics in the U.S. because of COVID-19, closely-held Field Trip Psychedelics is finding opportunities to expand its psychedelic...
Eyenovia (NASDAQ:EYEN) is using its unique microdose drug delivery technology, Optejet, to build a late-stage pipeline of ophthalmic therapeutics. “We have three late-stage programs for three major indications that we...
Daxor’s (NYSE American:DXR) BVA-100 blood volume measurement device is helping to open a new front in the battle against COVID-19. “Optimal volume management and knowledge of capillary status is key to survivability...
Closely-held Clarigent is developing a tool to support the early detection of mental health issues, with a goal of preventing suicide in at-risk children and adolescents. “The suicide rate, especially among school-aged...
Using its nanomedicine platform and the capabilities of its cGMP manufacturing facility, NanoViricides (NYSE American: NNVC) is developing therapeutics for a variety of viral infections, including herpes simplex viruses...
As chairman and CEO of Kleo Pharmaceuticals, a private immuno-oncology company developing next-generation bispecific compounds designed to enhance the activity of biologics, Dr. Doug Manion has a distinguished pedigree...
Since COVID-19 was first identified in China late last year, researchers have been working tirelessly to develop diagnostics, therapeutics and vaccines in an effort to prevent the spread of the SARS-CoV-2 virus. Many...
Using the natural pollination process of commercially-reared bees and biological products and controls, Bee Vectoring Technology International (TSXV, CVE:BEE; OTCQB:BEVVF) has developed a pest and disease solution for...
Obalon Therapeutics (NASDAQ:OBLN) is pivoting its business model to a retail strategy of company-managed clinics to deliver its Obalon Balloon System, a weight loss solution that is the first and only swallowable, gas...
Closely-held Diabeloop of Grenoble, France has developed an external Type 1 diabetes management system, known as DBLG1, that connects three components: a continuous glucose monitor, a patch-like insulin pump and an...
Anixa Biosciences (NASDAQ:ANIX) is taking multiple approaches to fighting cancer, developing both a diagnostic and therapeutics, such as a cancer immunotherapy and vaccine, to overcome immuno-suppression. Anixa...
Ocugen (NASDAQ:OCGN) is taking a multi-pronged approach to ophthalmology with a diversified pipeline that includes a breakthrough modifier gene therapy platform, novel biologics and small molecules, targeting a broad...
Using its unique ATLAS proprietary technology platform, Genocea Biosciences (NASDAQ:GNCA) is developing cancer immunotherapies that direct the body’s own tumor-fighting T-cells to the most therapeutically relevant...
Closely-held Ripple Therapeutics, a recent spinout from Interface Biologics, is pursuing a $25-million series A financing to complete a Phase 2 trial of IBE-814 IVT, a dexamethasone prodrug intravitreal implant, and...
Stereotaxis’ (NYSE American: STXS) launch in June 2019 of a next generation surgical robotic system, Genesis RMN, solidifies its commitment to innovation and collaboration as a stepping stone to improve patient care...
Closely-held pharmacogenetics company, Inagene Diagnostics, aims to replace the “trial-and-error” approach to pain management with a comprehensive genetic test that helps physicians provide personalized pain management...
Liminal BioSciences (NASDAQ, TSX:LMNL) is undergoing a significant strategic transformation to simplify its operations, achieve financial stability and focus R&D on small molecule therapeutics. “This is a refresh of...
BriaCell Therapeutics (OTCQB:BCTXD; TSXV:BCT) believes its Phase 2 clinical program in advanced breast cancer, which includes an ongoing combination study of its Bria-IMT with immune checkpoint inhibitors such as...